March 20th 2023
Combination treatment with nivolumab and relatlimab appears to be a safe treatment option for patients with advanced melanoma who have progressed on prior anti–PD-L1 therapy.
February 28th 2023
February 23rd 2023
Rule of 3 Proposed for Melanoma Genetic Testing in Countries With Lower Incidence
October 5th 2017In France and other countries with low to moderate incidence of melanoma, a new study has proposed recommending genetic testing using the rule of 3-screening those with 3 or more primary melanomas or genetically related cancers-instead of the rule of 2.
In this article, we provide an overview of the currently available systemic agents, including immunotherapeutic agents and targeted tyrosine kinase inhibitors. We also provide a practical management algorithm to guide the practicing oncologist in the use of both of these new therapies and the more traditional local treatments.
Much work has been done recently to try to determine the optimal therapies for brain metastases in melanoma patients, the most effective ways to combine them, and ideal radiation dose and fractions.
CheckMate 037: Nivolumab Improved Responses, Not Survival in Advanced Melanoma
July 17th 2017Patients with advanced melanoma treated with nivolumab had higher and more durable responses compared with investigator’s choice of chemotherapy, but these increases did not result in improved survival outcomes.
No Survival Increase in Melanoma With Completion Dissection for Sentinel Node Mets
June 22nd 2017Patients with node-positive intermediate-thickness melanoma had an increased rate of regional disease control when undergoing completion lymph-node dissection for sentinel node metastases, however, there was no increase in melanoma-specific survival.
Developments in the Screening and Prognostication of Melanoma
June 8th 2017This peer-to-peer discussion reviews the current strategies for managing patients with melanoma, including screening and prognosis for high-risk patients and how to choose the best therapies to avoid toxicities and treatment resistance.
Binimetinib/Encorafenib Combination Effective in BRAF-Mutant Melanoma
May 17th 2017Treatment with the combination of the MEK inhibitor binimetinib and the BRAF inhibitor encorafenib resulted in a superior progression-free survival for patients with advanced, unresectable BRAF-mutated melanoma compared with treatment with encorafenib alone.
Some Melanoma Survivors Still Practice Unsafe Sun Behaviors
March 12th 2017Although long-term melanoma survivors were more likely to report healthier levels of ultraviolet radiation exposure and sun protection behaviors than controls, some still reported indoor tanning or intentionally seeking sun to tan.
Age Restriction on Indoor Tanning Could Reduce Melanoma Incidence, Mortality
December 12th 2016Reducing the use of indoor tanning by enforcing an age restriction could potentially reduce melanoma incidence, mortality, and the costs associated with treating the disease, according to results of an economic analysis.